"PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab." by Gabriele Madonna

Selected Works of Carlo B. Bifulco, M.D.

Follow Contact

Article

PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab.

Oncoimmunology

Gabriele Madonna
Carmen Ballesteros-Merino, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA.
Zipei Feng, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA; Department of Cancer Biology, Oregon Health & Science University, Portland, OR, USA.
Carlo Bifulco, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA; Department of Pathology, Providence Portland Medical Center, Portland, OR, USA.
Mariaelena Capone
Diana Giannarelli
Domenico Mallardo
Ester Simeone
Antonio M Grimaldi
Corrado Caracò
Gerardo Botti
Bernard A Fox, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA; Department of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, OR, USA.
Paolo A Ascierto

Link

Document Type

Article

Publication Date

1-1-2018

Keywords

Immunotherapy,
Ipilimumab,
Melanoma,
PD-L1,
Tumor microenvironment,
genomics

Disciplines

Oncology

Clinical Institute

Cancer

Department

Earle A. Chiles Research Institute

Department

Oncology

Citation Information

Gabriele Madonna, Carmen Ballesteros-Merino, Zipei Feng, Carlo Bifulco, et al.. "PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab." Oncoimmunology (2018)
Available at: http://works.bepress.com/carlo-bifulco/29/